CLDN18.2 (Claudin 18.2)

CLDN18.2 (Claudin 18.2)

SKU: HT-628200
Lead Time
5-15 days
Shipping
Sea freight, Air freight, Express
Payment
T/T, L/C
Sample
Available

Product details

Product overview

Claudin is an integral membrane protein in the tight junction between epithelium and endothelium. The claudin 18 (CLDN18) molecule is an integral transmembrane protein (tetraspanin) with four transmembrane hydrophobic regions and two extracellular loops. CLDN18 exists in two different splice variants, CLDN18.1 and CLDN18.2. The splice variants CLDN18.1 and CLDN18.2 differ in the N-terminal part containing the first transmembrane (TM) region and loop 1, while the primary sequence of the protein at the C-terminus is identical.

 

​

 

CLDN18.1 is selectively expressed in cells of the normal lung, whereas CLDN18.2 is expressed only on gastric cells. However, the expression of CLDN18.2 in normal stomach is restricted to differentiated short-lived gastric epithelial cells. It has been confirmed that CLDN18.2 is expressed in a variety of tumor tissues. For example, CLDN18.2 has been found to be expressed in pancreatic, esophageal, gastric, bronchial, breast, and ENT tumors. CLDN18.2 is a valuable target for the prevention and/or treatment of primary tumors such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer (such as non-small cell lung cancer (NSCLC)), ovarian cancer, colon cancer, Liver cancer, head and neck cancer and gallbladder cancer and their metastasis, especially gastric cancer metastasis such as Krukenberg tumor, peritoneal metastasis and lymph node metastasis.

 

​

 

The differential expression of CLDN18.2 between cancer cells and normal cells, its membrane localization, its absence in most toxicity-related normal tissues, and its expression in the stomach are restricted to non-cancer cells that can be replenished by target-negative stem cells of the stomach. An essential cell population, differentiated gastric cells, makes CLDN18.2 an attractive target for cancer immunotherapy, and the use of antibody-based therapeutics (Therapeutics) targeting CLDN18.2 in cancer treatment enables high-level Therapeutic specificity becomes possible.

 

 

Human CLDN18.2(Fc tag)

 

Cat# Abt-P-4010 b

 

Expression host: HEK293

 

​Molecular weight: 36-40kDa

 

Concentration: 1-2mg/mL

 

Purity: >95%

 

Storage environment: 1×PBS (pH7.4)

 

Storage conditions: short-term storage at 4℃, long-term storage at -20℃. Avoid repeated freezing and thawing

 

Safety Tips: Not for human experimentation

Similar products

View all →
YT3-20
#msf-p-6486YT3-20
Quote on request

Others in Personal Care & Beauty Chemicals

View all →